ACP-01 Physician Education Expansion: Hemostemix Recruits Wound Care Champion to Transform Limb Preservation Practices

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has recruited Dr. David B. Alper, a nationally recognized podiatry physician and wound care leader, as Multidisciplinary Physician Education Lead to spearhead a comprehensive clinical engagement strategy across the United States, effective January 2026. This appointment marks a significant push to educate medical professionals on how autologous stem cell therapy addresses peripheral arterial disease and the underlying ischemia that drives limb amputation risk.

Striking Clinical Results Driving Education Push

The impetus behind this expanded physician education initiative stems from compelling clinical data. Hemostemix’s Phase II trial for chronic limb threatening ischemia demonstrated remarkable outcomes: 0% mortality across the treatment group followed for up to 4.5 years, compared to the standard 50% five-year mortality rate in untreated CLTI populations. Additionally, 83% of patients achieved wound healing, with complete cessation of pain reported—outcomes that reframe how root amputation risk can be managed through regenerative cell therapy.

“The scientific evidence supporting ACP-01 (VesCell™) justifies a fundamental shift in how clinicians approach these conditions,” explained Thomas Smeenk, CEO of Hemostemix. “Saving a limb is, quite literally, saving a life. Dr. Alper brings the clinical credibility and professional networks to translate this evidence into practice change.”

Three Parallel Education Initiatives

Dr. Alper will direct three interconnected programs designed to embed ACP-01 knowledge into clinical workflows:

Clinical Practice Engagement in Florida Direct collaboration with wound-care podiatrists and limb salvage teams to detail how VesCell addresses pain and the ischemia-root-cause of peripheral arterial disease and diabetic foot ulcers. This responsible clinical education model is designed to support increased adoption of ACP-01 within participating medical practices.

Podiatric Medical Education Engagement with Deans of Clinical Education at U.S. schools of podiatry medicine to introduce graduating doctors and faculty to ACP-01 as an intervention for limb-threatening ischemia, ensuring the next generation of practitioners understands regenerative approaches to amputation prevention.

Multidisciplinary Professional Forums Participation in educational conferences and forums spanning podiatrists, vascular specialists, interventional physicians, nurses, and wound-care professionals. Topics will include ischemic disease phenotyping, patient selection criteria, procedural considerations, and real-world integration of ACP-01 into team-based limb preservation practices.

Dr. Alper’s Credentials in Limb Preservation

Dr. Alper’s career has centered on amputation prevention and wound care leadership. He serves as a Trustee of the American Podiatric Medical Association, Fellow of the Royal College of Physicians and Surgeons of Glasgow, Adjunct Professor at Kent State University College of Podiatry Medicine, and Leadership Board member of the American Diabetes Association’s New England chapter (where he served as President for over 20 years). His board memberships span the Wound Care Collaborative Community, the Alliance for Woundcare Stakeholders, the Amputation Prevention Alliance, and the CLI Global Association—positioning him at the nexus of organizations focused on preventing limb loss through innovation and best practice dissemination.

About Hemostemix’s ACP-01 Platform

Hemostemix has completed seven clinical studies enrolling 318 subjects, with findings published in eleven peer-reviewed journals. ACP-01 (VesCell™) is an autologous blood-based stem cell therapy addressing peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, dilated cardiomyopathy, angina, congestive heart failure, and vascular dementia. The company’s Phase II CLTI trial results—featuring 0% mortality, pain cessation, and 83% wound healing rates—represent a substantial clinical advancement over standard-of-care outcomes in a patient population historically facing high amputation and mortality risk.